



August 08, 2023

To,

BSE Limited

Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001

Scrip code: 512529

National Stock Exchange of India Limited

Listing Department Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051

Symbol: SEQUENT

Subject: Appointment of Director

Dear Sir/ Madam,

Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015, we would like to inform you that the Board of Directors based on the recommendation of the Nomination and Remuneration Committee held on August 07, 2023, approved the appointment of Dr. Hari Babu Bodepudi (DIN: 01119678) as Additional Director (Non-Executive Non-Independent) w.e.f August 07, 2023.

Dr. Hari Babu Bodepudi will hold office until the conclusion of the ensuing Annual General Meeting of the Company and the Company will be seeking approval of the shareholders at the ensuing Annual General Meeting.

Brief profile and other Information of aforesaid Director pursuant to SEBI Circular bearing reference SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is mentioned in 'Annexure A' as enclosed herewith.

You are requested to take the same on record.

Yours faithfully, For Sequent Scientific Limited

Krunal Shah
Company Secretary & Compliance Officer

Encl.: A/a

Annexure A

1. Appointment of Dr. Hari Babu Bodepudi as an Additional Director

| Sr. | Particulars | Details of Change |
|-----|--|--|
| No | T di ticulai 3 | betails of change |
| 1. | Reason for change. viz. appointment, resignation, | Appointment |
| | removal, death or appointment otherwise | Dr. Hari Babu Bodepudi (DIN: 01119678) as an Additional Director (Non-Executive Non-Independent) |
| | | Dr. Hari Babu Bodepudi is a nominee of CA Harbor Investments (part of The Carlyle Group) |
| 2. | Date of appointment | 07.08.2023 |
| 3. | Term of appointment | Till the conclusion of the next annual general meeting. His office is liable to retire by rotation |
| 4. | Brief profile (in case of appointment) | Dr. Hari Babu Bodepudi holds a PhD degree in Organic Chemistry from Andhra University and has over 30 years of Industry experience permeating diverse roles in Research, Manufacturing, Quality and operations in both APIs and Oral Solids. |
| | | During the last 20 years, he held several leadership roles in technical and commercial operations in Mylan Laboratories, including being the COO of Mylan India, CEO of Mylan India and the Global COO of Mylan. |
| | | He was responsible for more than 50 Mylan facilities and managing more than 200 APIs and 15000 SKUs of different formulations. |
| | | At Mylan, he led Mylan's foray into the ARV business and grew that business to over USD800 mn with global leadership (in volume, value and portfolio spread) and more than 50% market share. |
| | | He has hands-on experience in global supply chain, regulatory, API R&D, quality and Commercial operations. |
| 5. | Disclosure of relationships between directors (in case of appointment of Director) | None |
| 6 | Disclosure | Dr. Hari Babu Bodepudi is not debarred from holding the office of Director by virtue of any order by the Securities and Exchange Board of India or any other authority. |